A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

NCT04525885 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Cough

Interventions

DRUG: Gefapixant 45 mg twice daily (BID)
DRUG: Gefapixant 15 mg BID
DRUG: Placebo
DRUG: Gefapixant 45 mg BID

Sponsor

Merck Sharp & Dohme LLC